Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Cited In for PubMed (Select 20414201)

1.

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.

Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S.

J Transl Med. 2015 Feb 26;13(1):74. doi: 10.1186/s12967-015-0427-y.

2.

Serum microRNA-128 as a biomarker for diagnosis of glioma.

Sun J, Liao K, Wu X, Huang J, Zhang S, Lu X.

Int J Clin Exp Med. 2015 Jan 15;8(1):456-63. eCollection 2015.

3.

Measuring the effects of aging and sex on regional brain stiffness with MR elastography in healthy older adults.

Arani A, Murphy MC, Glaser KJ, Manduca A, Lake DS, Kruse SA, Jack CR Jr, Ehman RL, Huston J 3rd.

Neuroimage. 2015 May 1;111:59-64. doi: 10.1016/j.neuroimage.2015.02.016. Epub 2015 Feb 17.

4.

Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma.

Tanase C, Albulescu R, Codrici E, Calenic B, Popescu ID, Mihai S, Necula L, Cruceru ML, Hinescu ME.

Onco Targets Ther. 2014 Dec 22;8:81-90. doi: 10.2147/OTT.S70886. eCollection 2015.

5.

Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.

Conroy S, Kruyt FA, Joseph JV, Balasubramaniyan V, Bhat KP, Wagemakers M, Enting RH, Walenkamp AM, den Dunnen WF.

PLoS One. 2014 Dec 29;9(12):e115687. doi: 10.1371/journal.pone.0115687. eCollection 2014.

6.

PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.

Zhang W, Lv S, Liu J, Zang Z, Yin J, An N, Yang H, Song Y.

Genet Mol Biol. 2014 Oct;37(4):716-24. doi: 10.1590/S1415-47572014005000011. Epub 2014 Oct 21.

7.

The orthotopic xenotransplant of human glioblastoma successfully recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model.

Garcia C, Dubois LG, Xavier AL, Geraldo LH, da Fonseca AC, Correia AH, Meirelles F, Ventura G, Romão L, Canedo NH, de Souza JM, de Menezes JR, Moura-Neto V, Tovar-Moll F, Lima FR.

BMC Cancer. 2014 Dec 8;14:923. doi: 10.1186/1471-2407-14-923.

8.

Economics of Malignant Gliomas: A Critical Review.

Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM.

J Oncol Pract. 2014 Dec 2. pii: JOP.2012.000560. [Epub ahead of print]

PMID:
25466707
9.

Nanotube x-ray for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment.

Zhang L, Yuan H, Inscoe C, Chtcheprov P, Hadsell M, Lee Y, Lu J, Chang S, Zhou O.

Expert Rev Anticancer Ther. 2014 Dec;14(12):1411-8. doi: 10.1586/14737140.2014.978293.

PMID:
25417729
11.

Lethal migration: the bradykinin story.

Gallo V.

J Physiol. 2014 Nov 15;592(Pt 22):4805-6. doi: 10.1113/jphysiol.2014.284455. Epub 2014 Sep 25. No abstract available.

PMID:
25260635
12.

The Study of "Dihydropyrimidinase Related Proteins (DRPs)" Expression Changes Influence in Malignant Astrocytoma Brain Tumor.

Pooladi M, Rezaei-Tavirani M, Hashemi M, Hesami-Tackallou S, Khaghani-Razi-Abad S, Moradi A, Zali AR, Mousavi M, Rakhshan A, Firozi-Dalvand L, Omidi R.

Iran J Cancer Prev. 2014 Summer;7(3):130-6.

13.

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.

Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L.

Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632.

14.

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.

Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML.

Viruses. 2014 Aug 12;6(8):3080-96. doi: 10.3390/v6083080.

15.

Emerging insights into barriers to effective brain tumor therapeutics.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H.

Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014. Review.

16.
17.

Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas.

Jha MK, Suk K.

Brain Tumor Res Treat. 2013 Oct;1(2):57-63. doi: 10.14791/btrt.2013.1.2.57. Epub 2013 Oct 31. Review.

18.

Glial progenitors as targets for transformation in glioma.

Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S, Weiss WA, Persson AI.

Adv Cancer Res. 2014;121:1-65. doi: 10.1016/B978-0-12-800249-0.00001-9. Review.

19.

Carbon nanotubes: an emerging drug carrier for targeting cancer cells.

Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, Pandit JK.

J Drug Deliv. 2014;2014:670815. doi: 10.1155/2014/670815. Epub 2014 Apr 24. Review.

20.

Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model.

Saga I, Shibao S, Okubo J, Osuka S, Kobayashi Y, Yamada S, Fujita S, Urakami K, Kusuhara M, Yoshida K, Saya H, Sampetrean O.

Neuro Oncol. 2014 Aug;16(8):1048-56. doi: 10.1093/neuonc/nou096. Epub 2014 May 23.

PMID:
24860177
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk